Pacific Biosciences of California (PACB) Set to Announce Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The business had revenue of $58.36 million for the quarter, compared to analyst estimates of $57.96 million. Pacific Biosciences of California had a negative return on equity of 40.23% and a negative net margin of 152.97%. The company’s quarterly revenue was up 113.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.35) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Trading Up 8.7 %

NASDAQ PACB opened at $1.99 on Tuesday. Pacific Biosciences of California has a 52 week low of $1.25 and a 52 week high of $14.55. The business has a 50 day moving average price of $3.31 and a 200-day moving average price of $6.12. The company has a quick ratio of 7.21, a current ratio of 7.81 and a debt-to-equity ratio of 1.27. The company has a market cap of $541.96 million, a price-to-earnings ratio of -1.64 and a beta of 1.99.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. JPMorgan Chase & Co. lowered Pacific Biosciences of California from an “overweight” rating to a “neutral” rating in a report on Monday, April 22nd. Barclays lowered their price target on Pacific Biosciences of California from $8.00 to $3.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 10th. StockNews.com raised shares of Pacific Biosciences of California to a “sell” rating in a report on Wednesday, April 17th. TD Cowen lowered their target price on shares of Pacific Biosciences of California from $12.00 to $2.50 and set a “buy” rating for the company in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group downgraded shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $7.00 to $2.50 in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.77.

Insider Transactions at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Oene Mark Van sold 33,560 shares of Pacific Biosciences of California stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $5.96, for a total transaction of $200,017.60. Following the transaction, the insider now directly owns 876,611 shares of the company’s stock, valued at $5,224,601.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Pacific Biosciences of California news, insider Oene Mark Van sold 33,560 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $5.96, for a total transaction of $200,017.60. Following the completion of the sale, the insider now directly owns 876,611 shares in the company, valued at $5,224,601.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David W. Meline acquired 40,000 shares of Pacific Biosciences of California stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $4.40 per share, for a total transaction of $176,000.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $176,000. The disclosure for this purchase can be found here. In the last three months, insiders sold 37,359 shares of company stock worth $218,843. 1.90% of the stock is currently owned by corporate insiders.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.